All News
Filter News
Found 809,010 articles
-
Vectura Group plc's Ultibro® Breezhaler® (QVA149) Approved for COPD Patients in Europe
9/24/2013
-
Aesica Fined After Man Sprayed With Chemical at Cramlington
9/24/2013
-
X-Chem Achieves Early Success in Collaboration With AstraZeneca PLC, Licenses Three Drug Discovery Programs
9/24/2013
-
University of Texas, Texas A&M University Study Reveals Why Men Cheat
9/24/2013
-
Forest Laboratories, Inc. Files Lawsuits Aagainst Several Companies for Infringement of Savella® Patents
9/24/2013
-
Fred Hutchinson Cancer Research Center Researchers Discover a New Way That Influenza Can Infect Cells
9/24/2013
-
Bayer AG Grabs Approval for Adempas® as First Drug to Treat Rare Heart and Lung Disease
9/24/2013
-
Data Show Sanofi (France)'s Lyxumia® Added to Basal Insulin Lowered Blood Sugar Especially When Fasting Plasma Glucose Was Controlled
9/24/2013
-
Purdue Pharma L.P. Receives FDA Approval for 15 mcg/hour Dosage Strength of Butrans® (Buprenorphine) Transdermal System CIII
9/24/2013
-
Man Becomes Drunk When Stomach Turns Into Brewery, International Journal of Clinical Medicine Reveals
9/24/2013
-
Furiex Pharmaceuticals, Inc. Confirms Takeda Pharmaceutical Co. Ltd. Receives European Marketing Authorization for VIPIDIA (alogliptin), VIPDOMET (alogliptin and metformin) and INCRESYNC (alogliptin and pioglitazone)
9/24/2013
-
BioCer Present Newly EU Approved Super Rapid Plant-Based Hemostat at EACTS
9/24/2013
-
Skin Drug Could Help Treat Type 1 Diabetes, Indiana University Study
9/24/2013
-
Cancer-Killing Cells Controlled by Epigenetic Process, University of Southern California Study
9/24/2013
-
Ligand Pharmaceuticals Inc. Partner GlaxoSmithKline Receives Marketing Authorization From the European Commission (EC) for Additional Revolade (Eltrombopag) Indication as the First Approved Treatment for Chronic Hepatitis C-Associated Thrombocytopenia
9/24/2013
-
Senomyx, Inc. Announces Management Update
9/24/2013
-
Techne Corp. Opens Up Under New CEO
9/24/2013
-
New Dwarfism Treatment Completely Restores Bone Growth in Mice, Mediterranean Center for Molecular Research Reveals
9/24/2013
-
Zealand Pharma Informs That Data Presented on Lyxumia® Support Known Complementary Effects of This Diabetes Medicine in Combination With Basal Insulin
9/24/2013
-
GTx, Inc. Announces Late Breaker Presentation on Results From the Two Phase 3 POWER Trials of Enobosarm, a Selective Androgen Receptor Modulator (SARM), for the Prevention and Treatment of Muscle Wasting in NSCLC Patients During 2013 European Cancer Congr
9/24/2013